Membrane-anchored GP41 peptides that inhibit subsequent HIV viral entry
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Sep 7, 2010
Grant Date -
N/A
app pub date -
Nov 24, 2000
filing date -
Nov 25, 1999
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention relates to the genetically engineered treatment of an HIV infection by the expression of membrane-anchored gp41 peptides. With this treatment vectors are made available for the first time which code for a fusion protein that contains a peptide derived from gp41 of HIV and a carboxy terminal by means of a trans-membrane anchor tagged to a flexible linker.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully